Effect of Vildagliptin vs. Metformin on hepatic steatosis in type 2 diabetic patients

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Emergency Medicine
Internal/Family Medicine
Surgery
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Thumbnail image
Detail Image
Detailed image
Book Detail
Upload PDF
Drug Updates issue 30Jan2025 -Shalina Medspace.pdf (117.2 KB)
Actions
Download in App
Promotional Categories
Featured
Countries of release
Angola
Central African Republic (CAR)
Democratic Republic of the Congo (DRC)
Ghana
India
Kenya
Nigeria
UAE
Zambia
IS_Ebsco
false
Description

In 246 newly diagnosed T2D patients, both vildagliptin and metformin improved glycaemic control (reduced FBG, HbA1c) and decreased HSI, body weight, and BMI, with metformin having a stronger effect on weight/BMI. Both drugs reduced hepatic steatosis, with total cholesterol and LDL as key predictors.

Published Date